Conatus Pharmaceuticals Inc.

NASDAQ: CNATHealthcare / Biotechnology / USA
0.920000.00Vol 161 5741Y Perf -81.09%
Jun 24th, 2019 16:00
BID0.9200 ASK0.9300
Open0.9300 Previous Close0.9200
Pre-Market- After-Trading0.36
 - -%  -0.56 -60.87%
Target Price
1.60 
Analyst Rating
Hold 3.00
Potencial %
73.91 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★+     49.64
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
★★     45.70
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)31 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
3.80 
Earnings Date
7th Aug 2019

Today's Price Range

0.86000.9500

52wk Range

0.69006.74

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
8.24%
3 Months
-28.13%
6 Months
-25.20%
1 Year
-81.09%
3 Years
-54.90%
5 Years
-89.26%

Name / TickerPriceChg.Chg.%
CNAT0.92000.00000.00
AAPL198.58-0.2000-0.10
GOOG1 115.52-6.3600-0.57
MSFT137.780.81000.59
XOM76.95-0.7400-0.95
WFC46.27-0.6200-1.32
JNJ143.060.97000.68
FB192.601.46000.76
GE10.28-0.2000-1.91
JPM108.66-0.7800-0.71
Earnings HistoryEstimateReportedSurprise %
Q01 2019-0.12-0.14-16.67
Q04 2018-0.14-0.137.14
Q03 2018-0.15-0.150.00
Q02 2018-0.20-0.1525.00
Q01 2018-0.17-0.170.00
Q04 2017-0.17-0.1511.76
Q03 2017-0.05-0.13-160.00
Q02 2017-0.11-0.19-72.73
Earnings Per EndEstimateRevision %Trend
6/2019 QR-0.12-9.09Negative
9/2019 QR-0.127.69Positive
12/2019 FY-0.48-6.67Negative
12/2020 FY-0.2545.65Positive
Next Report Date7th Aug 2019
Estimated EPS Next Report-0.12
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume161 574
Shares Outstanding (in ths.)33 165
Trades Count292
Dollar Volume141 456
Avg. Volume773 530
Avg. Weekly Volume719 633
Avg. Monthly Volume295 263
Avg. Quarterly Volume700 581
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (25.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (100.00 %)
3 (100.00 %)
3 (75.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingHold
3.00
Hold
3.00
Moderate Buy
2.50

Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc is a biotechnology company. It focuses on the development and commercialization of novel medicines to treat liver disease. The company is developing emricasan, an orally active pan-caspase protease inhibitor, for the treatment of patients with the chronic liver disease.

CEO: Steven J. Mento

Teplephone: +1 858 376-2600

Address: 16745 West Bernardo Drive, San Diego 92127, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

43%57%

Bearish Bullish

54%46%

Bearish Bullish

62%38%

News